The inhibition of gluconeogenesis by gatifloxacin may contribute to its hypoglycaemic action

European Journal of Pharmacology

Volumn 594, Issue 1-3, 2008, Pages 39-43

  Drozak, Jakub ^a   Miecznik, Anna ^a   Jarzyna, Robert ^a   Bryla, Jadwiga ^a  

^a UNIVERSITY OF WARSAW   (Poland)

Author keywords

Gatifloxacin; Gluconeogenesis; Hepatocytes; Mitochondria; Pyruvate uptake; Renal tubule

Indexed keywords

ADENOSINE DIPHOSPHATE; ALANINE; ALPHA CYANO 4 HYDROXYCINNAMIC ACID; ASPARTIC ACID; GATIFLOXACIN; GLYCEROL; MALIC ACID; OCTANOIC ACID; PYRUVIC ACID;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; DRUG ACCUMULATION; DRUG EFFECT; GLUCONEOGENESIS; KIDNEY CORTEX; KIDNEY TUBULE; LIVER CELL; MITOCHONDRIAL RESPIRATION; NONHUMAN; OXYGEN CONSUMPTION; PRIORITY JOURNAL; RABBIT;

ALANINE TRANSAMINASE; ANIMALS; ANTI-BACTERIAL AGENTS; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL TRANSPORT, ACTIVE; COUMARIC ACIDS; FLUOROQUINOLONES; GLUCONEOGENESIS; GLUTAMIC ACID; HEPATOCYTES; HYPOGLYCEMIC AGENTS; KIDNEY CORTEX; KIDNEY TUBULES; LIVER; MALATES; MALE; MITOCHONDRIA, LIVER; PYRUVATES; RABBITS;

EID: 50549088465     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.07.050     Document Type: Article

References (35)

1. Adrogue H.J. Glucose homeostasis and the kidney. Kidney Int. 42 (1992) 1266-1282
2. Al-Dgither S., Naseeruddin Alvi S., and Hammam M.M. Development and validation of an HPLC method for the determination of gatifloxacin stability in human plasma. J. Pharm. Biomed. Anal. 41 (2006) 251-255
3. Bergmeyer H.U. Methods of Enzymatic Analysis (1984), Verlag Chemie GmbH, Weinheim, Deerfield Beach, Florida-Basel
4. Bergmeyer H.U., and Bernt E. Glutamate-Pyruvate Transaminase. In: Bergmeyer H.U. (Ed). Methods in Enzymatic Analysis (1965), Academic Press, New York 846-851
5. Bhasin R., Arce F.C., and Pasmantier R. Hypoglycemia associated with the use of gatifloxacin. Am. J. Med. Sci. 330 (2005) 250-253
6. Bischof M.G., Krssak M., Krebs M., Bernroider E., Stingl E., Waldhausl W., and Roden M. Effects of short-term improvement of insulin treatment and glycemia on hepatic glycogen metabolism in type 1 diabetes. Diabetes 50 (2001) 392-398
7. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976) 248-254
8. Drozak J., Kozłowski M., Doroszewska R., Pera L., Derlacz R., Jarzyna R., and Bryla J. Differential effects of selegiline on glucose synthesis in rabbit kidney-cortex tubules and hepatocytes. In vitro and in vivo studies. Chem. Biol. Interact. 170 (2007) 162-176
9. FDA. Gatifloxacin (marketed as Tequin) Information (2006). http://www.fda.gov/cder/drug/infopage/gatifloxacin/ http://www.fda.gov/cder/drug/infopage/gatifloxacin/ accessed 21 June, 2008
10. Fish D.N., and North D.S. Gatifloxacin, an advanced 8-methoxy fluoroquinolone. Pharmacotherapy 21 (2001) 35-59
11. Ge T.F., Law P.Y., Wong H.Y., and Ho Y.Y. Gatifloxacin affects GLUT1 gene expression and disturbs glucose homeostasis in vitro. Eur. J. Pharmacol. 573 (2007) 70-74
12. Gerich J.E., Meyer C., Woerle H.J., and Stumvoll M. Renal gluconeogenesis: its importance in human glucose homeostasis. Diabetes Care 24 (2001) 382-391
13. Gómez-Lechón M.J., Castell J.V., and Donato M.T. Hepatocytes-the choice to investigate drug metabolism and toxicity in man: in vitro variability as a reflection of in vivo. Chem. Biol. Interact. 168 (2007) 30-50
14. Grasela D.M. Clinical pharmacology of gatifloxacin, a new fluoroquinolone. Clin. Infect. Dis. 31 Suppl 2 (2000) S51-S58
15. Halestrap A.P. The mitochondrial pyruvate carrier. Kinetics and specificity for substrates and inhibitors. Biochem. J. 148 (1975) 85-96
16. Harris E.J., Tate C., Manger J.R., and Bangham J.A. The effects of colloids on the appearance and substrate permeability of rat liver mitochondria. J. Bioenerg. 2 (1971) 221-232
17. Hildyard J.C., Ammälä C., Dukes I.D., Thomson S.A., and Halestrap A.P. Identification and characterisation of a new class of highly specific and potent inhibitors of the mitochondrial pyruvate carrier. Biochim. Biophys. Acta. 1707 (2005) 221-230
18. Honeybourne D., Banerjee D., Andrews J., and Wise R. Concentrations of gatifloxacin in plasma and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopy. J. Antimicrob. Chemother. 48 (2001) 63-66
19. Ishiwata Y., Sanada Y., and Yasuhara M. Effects of gatifloxacin on serum glucose concentration in normal and diabetic rats. Biol. Pharm. Bull. 29 (2006) 527-531
20. Jarzyna R., Kiersztan A., Lisowa O., and Bryla J. The inhibition of gluconeogenesis by chloroquine contributes to its hypoglycaemic action. Eur. J. Pharmacol. 428 (2001) 381-388
21. Kendall C., and Wooltorton E. People with diabetes should avoid antibiotic gatifloxacin. CMAJ 174 (2006) 1089-1090
22. Kiersztan A., Modzelewska A., Jarzyna R., Jagielska E., and Bryla J. Inhibition of gluconeogenesis by vanadium and metformin in kidney-cortex tubules isolated from control and diabetic rabbits. Biochem. Pharmacol. 63 (2002) 1371-1382
23. Krebs H.A., Cornell N.W., Lund P., and Hems R. Isolated liver cells as experimental material. In: Lundquist F., Tygstrup N., and Thysen J.H. (Eds). Regulation of Hepatic Metabolism (1974), Munksgaard, Copenhagen 726-750
24. Lietz T., and Bryla J. Glycerol and lactate induce reciprocal changes in glucose formation and glutamine production in isolated rabbit kidney-cortex tubules incubated with aspartate. Arch. Biochem. Biophys. 321 (1995) 501-509
25. Lietz T., Rybka J., and Bryla J. Fatty acids and glycerol or lactate are required to induce gluconeogenesis from alanine in isolated rabbit renal cortical tubules. Amino Acids 16 (1999) 41-58
26. Lohr J.W., Willsky G.R., and Acara M.A. Renal drug metabolism. Pharmacol. Rev. 50 (1998) 107-141
27. Park K., Williams D.P., Naisbitt D.J., Kitteringham N.R., and Pirmohamed M. Investigation of toxic metabolites during drug development. Toxicol. Appl. Pharmacol. 207 (2005) 425-434
28. Rocheleau J.V., Head W.S., Nicholson W.E., Powers A.C., and Piston D.W. Pancreatic islet beta-cells transiently metabolize pyruvate. J. Biol. Chem. 277 (2002) 30914-30920
29. Saraya A., Yokokura M., Gonoi T., and Seino S. Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K+ channels. Eur. J. Pharmacol. 516 (2004) 111-117
30. Thomas A.P., and Halestrap A.P. The role of mitochondrial pyruvate transport in the stimulation by glucagon and phenylephrine of gluconeogenesis from l-lactate in isolated rat hepatocytes. Biochem. J. 198 (1981) 551-560
31. Tomita T., Onishi M., Sato E., Kimura Y., and Kihira K. Gatifloxacin induces augmented insulin release and intracellular insulin depletion of pancreatic islet cells. Biol. Pharm. Bull. 30 (2007) 644-647
32. Usatenko M.S. Hormonal regulation of phosphoenolpyruvate carboxykinase activity in liver and kidney of adult animals and formation of this enzyme in developing rabbit liver. Biochem. Med. 3 (1970) 298-310
33. Williamson J.R., Kreisberg R.A., and Felts P.W. Mechanism for the stimulation of gluconeogenesis by fatty acids in perfused rat liver. Proc. Natl. Acad. Sci. U. S. A. 56 (1966) 247-254
34. Yamada C., Nagashima K., Takahashi A., Ueno H., Kawasaki Y., Yamada Y., Seino Y., and Inagaki N. Gatifloxacin acutely stimulates insulin secretion and chronically suppresses insulin biosynthesis. Eur. J. Pharmacol. 553 (2006) 67-72
35. Zaleski J., Zablocki K., and Bryla J. Short-term effect of glucagon on gluconeogenesis and pyruvate kinase in rabbit hepatocytes. Int. J. Biochem. 14 (1982) 733-739